INNV InnovAge Holding Corp.
Services-Health Services · Nasdaq · SEC CIK 1834376 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.1%
TTM net income YoY151.8%
TTM EPS YoY150.0%
Revenue 3-yr CAGR13.3%
Net income 3-yr CAGR—
Margins
Gross margin23.6%
Operating margin1.4%
Net margin0.9%
FCF margin7.5%
EBITDA margin3.6%
Returns
ROE3.6%
ROA1.7%
ROIC (approx.)5.4%
Asset turnover1.90x
Leverage & solvency
Liabilities / assets48.6%
Debt / equity0.19x
Current ratio1.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income9.95x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $989.71M | $853.70M |
| Gross profit | $227.76M | $153.64M |
| SG&A expense | $166.49M | $122.06M |
| Operating income | $2.62M | -$29.76M |
| Pretax income | $266,000 | -$34.03M |
| Income tax | $949,000 | $1.32M |
| Net income | -$2.54M | -$30.31M |
| EBITDA | $23.76M | -$10.25M |
| EPS (basic) | -0.02 | -0.22 |
| EPS (diluted) | -0.02 | -0.22 |
| Weighted avg. shares (diluted) | 135.70M | 135.39M |
| Balance sheet | ||
| Cash & equivalents | $97.89M | $64.14M |
| Short-term investments | $43.44M | $41.77M |
| Receivables | $42.39M | $36.37M |
| Current assets | $214.31M | $176.11M |
| PP&E, net | $166.09M | $168.04M |
| Goodwill | $142.05M | $142.05M |
| Intangibles | $3.22M | $3.88M |
| Total assets | $557.39M | $526.85M |
| Current liabilities | $203.89M | $164.81M |
| Short-term debt | $2.54M | $2.25M |
| Long-term debt | $45.52M | $57.46M |
| Total debt | $48.06M | $59.71M |
| Total liabilities | $288.62M | $263.94M |
| Shareholders' equity | $235.60M | $234.97M |
| Net debt | -$49.83M | -$4.43M |
| Shares outstanding | 136.02M | 135.44M |
| Cash flow statement | ||
| Operating cash flow | $64.71M | $32.87M |
| Capital expenditure | $14.31M | $6.26M |
| Free cash flow | $50.41M | $26.60M |
| Investing cash flow | -$12.34M | -$5.55M |
| Financing cash flow | -$18.53M | -$19.08M |
| Depreciation & amortization | $21.14M | $19.51M |
| Stock-based compensation | $7.05M | $7.62M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.